Regeneron Pharmaceuticals has been granted a patent for antibodies that bind to the glucagon-like peptide 1 receptor (GLP1R), potentially treating conditions associated with GLP1R in humans. The antibodies can elevate glucose levels to treat hypoglycemia, including post-bariatric hypoglycemia, by reducing insulin secretion. GlobalData’s report on Regeneron Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Regeneron Pharmaceuticals Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Regeneron Pharmaceuticals, Transgenic murine models was a key innovation area identified from patents. Regeneron Pharmaceuticals's grant share as of January 2024 was 39%. Grant share is based on the ratio of number of grants to total number of patents.

Antibodies for treating diseases associated with glp1r

Source: United States Patent and Trademark Office (USPTO). Credit: Regeneron Pharmaceuticals Inc

A recently granted patent (Publication Number: US11884736B2) discloses an antibody or antigen-binding fragment specifically targeting the glucagon-like peptide 1 receptor. The patent details the amino acid sequences of the heavy chain complementarity determining regions (HCDRs) and light chain CDRs within the antibody, providing specific sequences for HCVR and LCVR. The claims outline variations in the amino acid sequences of the HCDRs and LCDRs, offering multiple options for customization based on SEQ ID NOs.

Furthermore, the patent specifies the composition of the antibody or antigen-binding fragment, highlighting the amino acid sequences for both the heavy chain (HC) and light chain (LC). The claims present various combinations of SEQ ID NOs for the HC and LC, allowing for flexibility in designing the antibody. Additionally, the patent includes provisions for isolated antibodies that bind to the same epitope as the specified sequences, emphasizing the importance of targeting the glucagon-like peptide 1 receptor. The patent also extends to pharmaceutical compositions containing the isolated antibody or antigen-binding fragment along with a pharmaceutically acceptable carrier or diluent, indicating potential applications in the medical field.

To know more about GlobalData’s detailed insights on Regeneron Pharmaceuticals, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies